BDTX

Company Overview — What Does Black Diamond Therapeutics, Inc. Do?

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Black Diamond Therapeutics, Inc. (BDTX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David M. Epstein and employs approximately 90 people. With a market capitalization of $133M, BDTX is one of the notable companies in the Healthcare sector.

Black Diamond Therapeutics, Inc. (BDTX) Stock Rating — Reduce (April 2026)

As of April 2026, Black Diamond Therapeutics, Inc. receives a Reduce rating with a composite score of 39.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.BDTX ranks #2,458 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Black Diamond Therapeutics, Inc. ranks #305 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BDTX Stock Price and 52-Week Range

Black Diamond Therapeutics, Inc. (BDTX) currently trades at $2.55. The stock lost $0.03 (1.2%) in the most recent trading session. The 52-week high for BDTX is $4.94, which means the stock is currently trading -48.4% from its annual peak. The 52-week low is $1.20, putting the stock 113.4% above its annual trough. Recent trading volume was 877K shares, suggesting relatively thin trading activity.

Is BDTX Overvalued or Undervalued? — Valuation Analysis

Black Diamond Therapeutics, Inc. (BDTX) carries a value factor score of 72/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 6.40x, compared to the Healthcare sector average of 23.63x — a discount of 73%. The price-to-book ratio stands at 1.25x, versus the sector average of 2.75x. The price-to-sales ratio is 2.01x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, BDTX trades at 11.69x EV/EBITDA, versus 6.34x for the sector.

Based on these multiples, Black Diamond Therapeutics, Inc. appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.

Black Diamond Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Black Diamond Therapeutics, Inc. (BDTX) earns a quality factor score of 28/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 19.5%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 15.3% versus the sector average of -33.1%.

The operating margin is 77.9% (sector: -66.1%). Net profit margin stands at 80.8%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

BDTX Debt, Balance Sheet, and Financial Health

Black Diamond Therapeutics, Inc. has a debt-to-equity ratio of 27.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 8.42x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $31M.

BDTX has a beta of 1.56, meaning it is more volatile than the broader market — a $10,000 investment in BDTX would be expected to move 55.8% more than the S&P 500 on any given day. The stability factor score for Black Diamond Therapeutics, Inc. is 25/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Black Diamond Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Black Diamond Therapeutics, Inc. reported revenue of $70M and earnings per share (EPS) of $0.39. Net income for the quarter was $22M. Operating income came in at $12M.

In FY 2025, Black Diamond Therapeutics, Inc. reported revenue of $70M and earnings per share (EPS) of $0.39. Net income for the quarter was $22M. Operating income came in at $13M.

In Q3 2025, Black Diamond Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.15. Net income for the quarter was $-8M. Operating income came in at $-11M.

In Q2 2025, Black Diamond Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.19. Net income for the quarter was $-11M. Operating income came in at $-13M.

Over the past 8 quarters, Black Diamond Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $70M. Investors analyzing BDTX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BDTX Dividend Yield and Income Analysis

Black Diamond Therapeutics, Inc. (BDTX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BDTX Momentum and Technical Analysis Profile

Black Diamond Therapeutics, Inc. (BDTX) has a momentum factor score of 44/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 47/100 reflects moderate short selling activity.

BDTX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Black Diamond Therapeutics, Inc. (BDTX) ranks #305 out of 838 stocks based on the Blank Capital composite score. This places BDTX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BDTX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BDTX vs S&P 500 (SPY) comparison to assess how Black Diamond Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

BDTX Next Earnings Date

No upcoming earnings date has been announced for Black Diamond Therapeutics, Inc. (BDTX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BDTX? — Investment Thesis Summary

The quantitative profile for Black Diamond Therapeutics, Inc. suggests caution. The quality score of 28/100 flags below-average profitability. The value score of 72/100 suggests attractive pricing relative to fundamentals. High volatility (stability score 25/100) increases portfolio risk.

In summary, Black Diamond Therapeutics, Inc. (BDTX) earns a Reduce rating with a composite score of 39.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BDTX stock.

Related Resources for BDTX Investors

Explore more research and tools: BDTX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BDTX head-to-head with peers: BDTX vs AZN, BDTX vs SLGL, BDTX vs VMD.